ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Kalinsky on Neratinib and Tucatinib in HER2+ Metastatic Breast Cancer

Kevin Kalinsky, MD, MS
Published: Wednesday, Aug 08, 2018



Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer. 

Data from the TBCRC 022 trial, Kalinsky says, suggested that patients demonstrated responses under single-agent neratinib. There was also a randomized phase III study looking at frontline paclitaxel and trastuzumab (Herceptin) versus paclitaxel and neratinib. Risk of metastases progression was half for patients under the neratinib and paclitaxel arm compared with trastuzumab and paclitaxel, Kalinsky says.

Tucatinib, a tyrosine kinase inhibitor that is specific to HER2-targeted therapy, is another emerging agent with some interesting data, Kalinsky adds. The ongoing HER2CLIMB study is testing the drug in a triplet combination with trastuzumab and capecitabine (Xeloda).
 


Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer. 

Data from the TBCRC 022 trial, Kalinsky says, suggested that patients demonstrated responses under single-agent neratinib. There was also a randomized phase III study looking at frontline paclitaxel and trastuzumab (Herceptin) versus paclitaxel and neratinib. Risk of metastases progression was half for patients under the neratinib and paclitaxel arm compared with trastuzumab and paclitaxel, Kalinsky says.

Tucatinib, a tyrosine kinase inhibitor that is specific to HER2-targeted therapy, is another emerging agent with some interesting data, Kalinsky adds. The ongoing HER2CLIMB study is testing the drug in a triplet combination with trastuzumab and capecitabine (Xeloda).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x